Montaner JS - Search Results

1

Factors associated with disclosure of HIV status among a cohort of individuals on antiretroviral therapy in British Columbia, Canada.

Hirsch Allen AJ, Forrest JI, Kanters S, O'Brien N, Salters KA, McCandless L, Montaner JS, Hogg RS. Hirsch Allen AJ, et al. Among authors: montaner js. AIDS Behav. 2014 Jun;18(6):1014-26. doi: 10.1007/s10461-013-0623-9. AIDS Behav. 2014. PMID: 24114265

2

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.

Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, Montaner JS, O'Shaughnessy MV, Schechter MT. Wood E, et al. Among authors: montaner js. AIDS. 2002 Apr 12;16(6):941-3. doi: 10.1097/00002030-200204120-00021. AIDS. 2002. PMID: 11919503

3

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.

Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS. Hogg RS, et al. Among authors: montaner js. AIDS. 2002 May 3;16(7):1051-8. doi: 10.1097/00002030-200205030-00012. AIDS. 2002. PMID: 11953472

4

Prescribing practices in a population-based HIV postexposure prophylaxis program.

Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS. Braitstein P, et al. Among authors: montaner js. AIDS. 2002 May 3;16(7):1067-70. doi: 10.1097/00002030-200205030-00014. AIDS. 2002. PMID: 11953474

5

To stop or not to stop: that is the question, but what is the answer?

Hogg RS, Havlir D, Miller V, Montaner JS. Hogg RS, et al. Among authors: montaner js. AIDS. 2002 Mar 29;16(5):787-9. doi: 10.1097/00002030-200203290-00015. AIDS. 2002. PMID: 11964536 No abstract available.

6

Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.

Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS. Braitstein P, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):547-8. doi: 10.1097/00126334-200204150-00019. J Acquir Immune Defic Syndr. 2002. PMID: 11981375 No abstract available.

7

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66. doi: 10.1097/00042560-200206010-00004. J Acquir Immune Defic Syndr. 2002. PMID: 12045678 Clinical Trial.

8

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Heath KV, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):440-7. doi: 10.1097/00042560-200208010-00010. J Acquir Immune Defic Syndr. 2002. PMID: 12138351

9

Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States.

Chan KC, Yip B, Hogg RS, Montaner JS, O'Shaughnessy MV. Chan KC, et al. Among authors: montaner js. AIDS. 2002 Aug 16;16(12):1693-5. doi: 10.1097/00002030-200208160-00020. AIDS. 2002. PMID: 12172096 No abstract available.

10

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. Among authors: montaner js. AIDS. 2002 Sep 27;16(14):1929-33. doi: 10.1097/00002030-200209270-00010. AIDS. 2002. PMID: 12351953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

824 results

Search Page

Filters